Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Bruce W, Kirkham"'
Autor:
Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1127-1146 (2023)
Abstract Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40–60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antib
Externí odkaz:
https://doaj.org/article/4c9392c1257a45e0b15c5bcafb3f3df9
Autor:
Sam Norton, Bruce W Kirkham, James Galloway, Khaldoun Chaabo, Toby Garrood, Zoe Rutter-Locher, Estee Chan, Alex Vincent
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Introduction Despite better therapies and strategies, many people with rheumatoid arthritis (RA) have persistent pain, often from abnormal pain processing, now termed nociplastic pain. However, RA patients with fibromyalgia (FM), a central nociplasti
Externí odkaz:
https://doaj.org/article/9f332f35f41242d5b9cf229f9367f721
Autor:
René E M Toes, Bruce W Kirkham, L A Trouw, Michelle D van den Beukel, Leonie S Taams, Catherine D Hughes, Sarah E Ryan, Kathryn J A Steel, Karin A J van Schie, Bina Menon
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objective Undifferentiated, early inflammatory arthritis (EIA) can differentiate into seropositive or seronegative rheumatoid arthritis (RA), peripheral spondyloarthritis (SpA) or remain as seronegative undifferentiated inflammatory arthritis (UIA).
Externí odkaz:
https://doaj.org/article/1632d54ad26941bea5e5f23ce49f79fa
Autor:
Iain B McInnes, Stefan Siebert, Paul Bowness, Laura C Coates, Anne Francis, Bruce W Kirkham, Alexander Ooms, Hussein Al-Mossawi, Louise Bennett, Nicole Yager, Duncan Richards, Mimi Bogale, Carl Goodyear, Sylvine Lalnunhlimi, Leonie S Taams, Aysin Tulunay Virlan
Publikováno v:
BMJ Open, Vol 13, Iss 9 (2023)
Introduction Psoriatic arthritis (PsA) affects around 150 000 people in the UK of whom around 50% require treatment with biologics. The most used biologics for PsA target tumour necrosis factor (TNF) or interleukin-17A (IL-17A). About 50% of patients
Externí odkaz:
https://doaj.org/article/fec1e3e94bdb470b8bf658b6414ae65c
Autor:
Giovanni A.M. Povoleri, Lucy E. Durham, Elizabeth H. Gray, Sylvine Lalnunhlimi, Shichina Kannambath, Michael J. Pitcher, Pawan Dhami, Thomas Leeuw, Sarah E. Ryan, Kathryn J.A. Steel, Bruce W. Kirkham, Leonie S. Taams
Publikováno v:
Cell Reports, Vol 42, Iss 5, Pp 112514- (2023)
Summary: CD69+CD103+ tissue-resident memory T (TRM) cells are important drivers of inflammation. To decipher their role in inflammatory arthritis, we apply single-cell, high-dimensional profiling to T cells from the joints of patients with psoriatic
Externí odkaz:
https://doaj.org/article/7c887f70768745f6826a22484fb9b917
Autor:
Peter Nash, Luminita Pricop, Bruce W Kirkham, Alexis Ogdie, Effie Pournara, Christopher T Ritchlin, Matthias Kormaksson, Gregory Ligozio
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/07fa0ebc62d94151b4fe1e0af203bd1b
Autor:
Nicola J. Gullick, Fowzia Ibrahim, Ian C. Scott, Alexandra Vincent, Andrew P. Cope, Toby Garrood, Gabriel S. Panayi, David L. Scott, Bruce W. Kirkham, On behalf of TITRATE Programme Investigators
Publikováno v:
BMC Rheumatology, Vol 3, Iss 1, Pp 1-10 (2019)
Abstract Background The emphasis on treating rheumatoid arthritis (RA) intensively reduces disease activity but its impact in routine care is uncertain. We evaluated temporal changes in disease activities and outcomes in a 10-year prospective observa
Externí odkaz:
https://doaj.org/article/5ed2d01ef5e44e2386a0fa67a88ad154
Autor:
Ernest Choy, Xenofon Baraliakos, Frank Behrens, Salvatore D’Angelo, Kurt de Vlam, Bruce W. Kirkham, Mikkel Østergaard, Georg A. Schett, Michael Rissler, Kamel Chaouche-Teyara, Chiara Perella
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)
Abstract Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are a
Externí odkaz:
https://doaj.org/article/bcfaeb54cfae4cbaa978343733a93070
Autor:
Frances Humby, Sujith Subesinghe, Andrew Cope, Bina Menon, Rachel Byng-Maddock, Nadia Ladha Hassan, Laura Blackler, Zoe Mckee, Karen Topping, Lydia Marsh, Toby Garrood, Nora Ng, Bruce W Kirkham
Publikováno v:
Rheumatology. 62
Background/Aims In England, patients with rheumatoid arthritis (RA) with Moderate Disease Activity (MDAS), assessed by the DAS28 measure, had been unable to access effective therapies. We and others have reported that this group has persistent active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcb85cf5265a0e504bb782a78b48cf05
https://doi.org/10.1093/rheumatology/kead104.326
https://doi.org/10.1093/rheumatology/kead104.326
Autor:
Bruce W Kirkham, Elena Nikiphorou, Christopher J Edwards, Mohamed Sheesh, Ewa Haladyj, Jens Gerwien, Liliana Zaremba-Pechmann, Peter C Taylor
Publikováno v:
Rheumatology. 62
Background/Aims Baricitinib, an oral selective JAK 1/2 inhibitor, is approved for treating adults with moderate-to-severe active rheumatoid arthritis (RA). This analysis aims to report the efficacy of baricitinib in patients with moderate RA at weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8148fe85cb97c7882476579e50efdb86
https://doi.org/10.1093/rheumatology/kead104.168
https://doi.org/10.1093/rheumatology/kead104.168